ARCA biopharma Inc
For the period ended Dec 31, 2023. Filed Feb 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 1, 2024
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
STATEMENTS OF OPERATIONS
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| (in thousands, except shareand per share amounts) | ||
| Costs and expenses: | ||
| General and administrative | $6,283 | $5,847 |
| Research and development (related party - $(91) and $432 as of the years ended December 31, 2023 and 2022, respectively) | 1,013 | 4,749 |
| Total costs and expenses | 7,296 | 10,596 |
| Loss from operations | (7,296) | (10,596) |
| Interest and other income | 1,957 | 675 |
| Other loss | — | (5) |
| Net loss | $(5,339) | $(9,926) |
| Net loss per share: | ||
| Basic and diluted | $(0.37) | $(0.69) |
| Weighted average shares outstanding: | ||
| Basic and diluted | 14,415,877 | 14,410,143 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.